CEL-SCI Corp (CVM)
1.42
-0.09
(-5.96%)
USD |
NYAM |
May 10, 16:00
1.42
0.00 (0.00%)
After-Hours: 20:00
CEL-SCI Enterprise Value: 78.27M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 78.27M |
May 08, 2024 | 71.79M |
May 07, 2024 | 86.90M |
May 06, 2024 | 89.60M |
May 03, 2024 | 84.74M |
May 02, 2024 | 76.65M |
May 01, 2024 | 73.41M |
April 30, 2024 | 75.57M |
April 29, 2024 | 72.87M |
April 26, 2024 | 74.49M |
April 25, 2024 | 75.03M |
April 24, 2024 | 75.57M |
April 23, 2024 | 76.11M |
April 22, 2024 | 78.27M |
April 19, 2024 | 80.97M |
April 18, 2024 | 77.73M |
April 17, 2024 | 77.73M |
April 16, 2024 | 78.81M |
April 15, 2024 | 82.59M |
April 12, 2024 | 84.74M |
April 11, 2024 | 86.36M |
April 10, 2024 | 86.90M |
April 09, 2024 | 89.06M |
April 08, 2024 | 92.84M |
April 05, 2024 | 92.30M |
Date | Value |
---|---|
April 04, 2024 | 90.68M |
April 03, 2024 | 96.62M |
April 02, 2024 | 93.38M |
April 01, 2024 | 95.54M |
March 28, 2024 | 99.86M |
March 27, 2024 | 98.78M |
March 26, 2024 | 98.24M |
March 25, 2024 | 84.74M |
March 22, 2024 | 95.54M |
March 21, 2024 | 98.78M |
March 20, 2024 | 103.64M |
March 19, 2024 | 106.34M |
March 18, 2024 | 107.42M |
March 15, 2024 | 105.26M |
March 14, 2024 | 110.65M |
March 13, 2024 | 108.50M |
March 12, 2024 | 110.65M |
March 11, 2024 | 116.05M |
March 08, 2024 | 120.37M |
March 07, 2024 | 119.83M |
March 06, 2024 | 126.85M |
March 05, 2024 | 117.13M |
March 04, 2024 | 121.45M |
March 01, 2024 | 117.67M |
February 29, 2024 | 109.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.60M
Minimum
Oct 20 2023
1.105B
Maximum
Apr 27 2021
297.62M
Average
236.46M
Median
Enterprise Value Benchmarks
AIM ImmunoTech Inc | 9.406M |
IGC Pharma Inc | 31.90M |
NovaBay Pharmaceuticals Inc | 2.645M |
Protalix BioTherapeutics Inc | 67.01M |
Palatin Technologies Inc | 28.44M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.710M |
Total Expenses (Quarterly) | 6.486M |
EPS Diluted (Quarterly) | -0.14 |
Earnings Yield | -47.89% |